PERFLUBRON - Generic Drug Details

What are the generic sources for perflubron and what is the scope of patent protection?

Perflubron is the generic ingredient in one branded drug marketed by Alliance Pharm and is included in one NDA. Additional information is available in the individual branded drug profile pages.

Summary for PERFLUBRON

US Patents:	0
Tradenames:	1
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	96
Clinical Trials:	4
DailyMed Link:	PERFLUBRON at DailyMed

Recent Clinical Trials for PERFLUBRON

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
SolAeroMed Inc.	Phase 2
Children's Hospital of Philadelphia	Phase 1
Auto Dealers Caring for Kids Foundation	Phase 1

See all PERFLUBRON clinical trials

Anatomical Therapeutic Chemical (ATC) Classes for PERFLUBRON

V08CX	Other magnetic resonance imaging contrast media
V08C	MAGNETIC RESONANCE IMAGING CONTRAST MEDIA
V08	CONTRAST MEDIA
V	Various

US Patents and Regulatory Information for PERFLUBRON

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Alliance Pharm	IMAGENT	perflubron	LIQUID;ORAL	020091-001	Aug 13, 1993		DISCN	No	No

Perflubron: Market Dynamics and Financial Trajectory Analysis

Last updated: February 18, 2026

This report analyzes the market dynamics and financial trajectory of perflubron, a liquid perfluorocarbon with potential therapeutic applications. Current market penetration is minimal, primarily confined to investigational uses. Financial projections are contingent on regulatory approvals and successful clinical development.

What is Perflubron and Its Current Applications?

Perflubron is a synthetic perfluorocarbon (PFC) compound with the chemical formula C₃F₇Br. Its unique properties, including high oxygen solubility and inertness, have driven research into its therapeutic potential. The primary focus of development has been as an artificial blood substitute and in lung liquid ventilation (LLV).

Currently, perflubron has not achieved broad market approval for commercial sale as a drug. Its use is largely restricted to:

• Research and Development: Pharmaceutical companies and academic institutions utilize perflubron in preclinical studies and early-stage clinical trials to assess its efficacy and safety for various medical conditions.
• Investigational Use: In specific clinical settings, perflubron has been used under investigational new drug (IND) protocols for conditions such as acute respiratory distress syndrome (ARDS) and neonatal respiratory distress. For example, studies have explored its application in delivering oxygen to critically ill patients with severe lung injury [1].

The current market size for perflubron as a finished pharmaceutical product is negligible. Its financial trajectory is therefore linked to future development milestones rather than existing sales.

What are the Key Therapeutic Areas for Perflubron?

The therapeutic applications for perflubron are centered around its ability to carry and deliver oxygen and its inertness, making it suitable for direct contact with biological tissues.

Key therapeutic areas under investigation include:

• Acute Respiratory Distress Syndrome (ARDS): Perflubron has been investigated for liquid ventilation in patients with ARDS. This technique involves filling the lungs with a liquid capable of dissolving large amounts of oxygen and carbon dioxide, potentially improving gas exchange and reducing ventilator-induced lung injury [2]. Clinical trials have explored its use as an adjunct to mechanical ventilation.
• Neonatal Respiratory Distress Syndrome (NRDS): In premature infants, NRDS is caused by insufficient surfactant production. Perflubron has been studied as a liquid breathing medium to support lung function in these vulnerable patients.
• Pulmonary Drug Delivery: The high gas solubility of perflubron allows it to act as a carrier for dissolved drugs. Research has explored its potential for delivering therapeutic agents directly to the lungs, targeting lung diseases with improved local concentration and reduced systemic side effects.
• Artificial Blood Substitute: While not its primary current focus, perflubron's oxygen-carrying capacity has led to investigations into its use as a temporary oxygen carrier in cases of severe anemia or blood loss. However, this application faces significant competition from other oxygen carriers and challenges related to immunogenicity and clearance.

The development pathway for perflubron in these areas is characterized by significant scientific and regulatory hurdles.

What is the Regulatory Status of Perflubron?

The regulatory status of perflubron is a critical determinant of its market access and financial viability. As of current data, perflubron does not hold widespread market approval from major regulatory bodies for general pharmaceutical use.

• United States (FDA): Perflubron has undergone investigation and has been used under Investigational New Drug (IND) applications. However, it has not received approval from the Food and Drug Administration (FDA) for any specific therapeutic indication. The pathway to approval would require robust clinical trial data demonstrating safety and efficacy that meets FDA standards.
• European Union (EMA): Similar to the FDA, the European Medicines Agency (EMA) has not approved perflubron for pharmaceutical sale. Any future application would necessitate a comprehensive dossier submitted through the centralized or national procedures.
• Other Jurisdictions: Regulatory agencies in other countries, such as Japan's Pharmaceuticals and Medical Devices Agency (PMDA) or Health Canada, also do not list perflubron as an approved pharmaceutical product.

The lack of regulatory approval means that perflubron cannot be prescribed or sold as a therapeutic drug in most major markets. Companies pursuing its development must navigate complex and lengthy regulatory pathways, typically involving Phase I, II, and III clinical trials, followed by a New Drug Application (NDA) or equivalent submission.

What are the Primary Challenges and Risks Associated with Perflubron Development?

The development of perflubron faces several significant challenges and risks that impact its market potential and financial outlook.

Key challenges include:

• Clinical Efficacy and Safety: Demonstrating statistically significant clinical efficacy for perflubron across its proposed indications remains a primary hurdle. Furthermore, long-term safety profiles and potential adverse events, such as pulmonary inflammation or impaired surfactant function, require thorough investigation.
• Regulatory Approval Hurdles: As noted, obtaining approval from regulatory agencies like the FDA and EMA is a protracted and expensive process. Past clinical trials may not have met the stringent endpoints required for approval, necessitating new study designs and potentially larger patient populations.
• Competition: Perflubron faces competition from established treatments and emerging therapeutic modalities in its target areas.
  • ARDS: Current management of ARDS involves supportive care, including mechanical ventilation strategies and pharmacological interventions. New ARDS therapies are also in development, including immunomodulators and anti-inflammatory agents.
  • Neonatal Respiratory Support: Surfactant replacement therapy is the standard of care for NRDS. While perflubron offers a different approach, it must demonstrate superior outcomes or a complementary benefit to justify its adoption.
  • Oxygen Carriers: The market for artificial blood substitutes or oxygen carriers is competitive, with various technologies being explored. Perflubron's therapeutic window and long-term effects need to be clearly defined against these alternatives.
• Manufacturing and Formulation: Scaling up manufacturing of perflubron to meet pharmaceutical standards while maintaining purity and consistency can be complex. The formulation for administration, particularly for liquid ventilation, requires specialized equipment and trained personnel.
• Cost-Effectiveness and Reimbursement: If perflubron eventually gains approval, its price point will be a critical factor. Demonstrating cost-effectiveness compared to existing treatments will be essential for securing favorable reimbursement from healthcare payers. The specialized nature of its administration might also lead to higher healthcare system costs.
• Intellectual Property Landscape: The patent landscape surrounding perflubron and its applications is crucial. Existing patents may limit freedom to operate, and new patent filings must demonstrate genuine innovation to secure market exclusivity.

These risks collectively influence investment decisions and the projected financial trajectory of perflubron.

What is the Current Market Landscape and Competitive Environment for Perflubron?

The current market landscape for perflubron is characterized by its absence as a commercially available pharmaceutical product. Its competitive environment is thus defined by the existing standard of care and ongoing research into alternative therapies.

• Market Presence: Perflubron has no significant market share. Its presence is confined to research laboratories and select clinical investigational sites. There are no publicly traded companies with perflubron as a marketed product generating revenue.
• Key Players in R&D: Research into perflubron has historically involved academic institutions and specific pharmaceutical companies. Companies involved in PFC chemistry or advanced respiratory therapies might hold intellectual property or ongoing research programs. However, identifying specific entities with current large-scale commercial development programs is challenging due to the early-stage and often proprietary nature of drug development. Companies like Alliance Pharmaceuticals (formerly in collaboration with Northfield Laboratories) have been associated with perflubron research in the past [3].
• Competitive Technologies in ARDS:
  • Mechanical Ventilation: The mainstay of ARDS treatment. Research focuses on optimizing ventilator settings to minimize lung injury (e.g., lung protective ventilation).
  • ECMO (Extracorporeal Membrane Oxygenation): A life-support technology for severe respiratory or cardiac failure.
  • Pharmacological Agents: Various drugs are investigated or used off-label to manage ARDS complications, including anti-inflammatories, corticosteroids, and treatments for underlying causes.
• Competitive Technologies in Neonatal Respiratory Support:
  • Exogenous Surfactant Therapy: Administered directly into the lungs to improve lung compliance and gas exchange. This is the standard of care.
  • CPAP (Continuous Positive Airway Pressure) and Mechanical Ventilation: Supportive respiratory therapies.
• Oxygen Carriers: The field of artificial blood substitutes includes hemoglobin-based oxygen carriers (HBOCs) and perfluorocarbon-based oxygen carriers (PFOCs). Examples of HBOCs that have undergone clinical trials include diaspirin cross-linked hemoglobin (DCLHb) and Hemopure (hemoglobin glutamer-200). PFOCs are a broad class, with perflubron being one specific compound.

The competitive environment is dynamic, with constant innovation. For perflubron to gain traction, it must demonstrate a clear clinical advantage, an acceptable safety profile, and economic viability compared to established and emerging alternatives.

What are the Projected Financial Trajectories and Investment Potential for Perflubron?

Projecting the financial trajectory of perflubron is highly speculative due to its lack of market approval and the inherent risks in pharmaceutical development. Investment potential is currently limited to early-stage research and development funding or strategic investments in companies holding relevant intellectual property.

• Current Financial Status: Perflubron as a product generates no revenue. Any financial activity is related to R&D expenditures, intellectual property management, and potential early-stage funding rounds for companies or research groups involved in its development.
• Potential Future Revenue Streams: Should perflubron successfully navigate clinical trials and gain regulatory approval for specific indications (e.g., ARDS treatment), revenue would be generated through:
  • Product Sales: Direct sales of the approved pharmaceutical product to hospitals, clinics, and potentially specialty pharmacies.
  • Licensing Agreements: Companies holding patents might license the technology to larger pharmaceutical firms for commercialization, generating milestone payments and royalties.
  • Service Contracts: If administration requires specialized equipment or personnel, service and maintenance contracts could represent a revenue stream.
• Valuation Metrics: Valuations of perflubron as an asset would depend on:
  • Stage of Development: Pre-clinical, Phase I, II, or III.
  • Probability of Regulatory Success: Based on interim trial data and expert assessment.
  • Market Size and Penetration Potential: The addressable patient population and projected market share for approved indications.
  • Competitive Landscape: Strength of competing therapies.
  • Intellectual Property Strength: Duration and breadth of patent protection.
• Investment Horizon: Investments in perflubron would be long-term, with potential returns only materializing after successful regulatory approvals, which can take 5-10 years or more.
• Risk-Adjusted Returns: The high failure rate in drug development means that potential investors must factor in significant risk. The investment potential is thus tied to the perceived likelihood of overcoming the scientific, regulatory, and commercial hurdles.
• Estimated Development Costs: Bringing a new drug to market can cost hundreds of millions to over a billion dollars. Perflubron development costs would include extensive pre-clinical testing, multiple phases of human clinical trials, regulatory submissions, and manufacturing scale-up.

Without specific ongoing development programs with public financial reporting, it is impossible to provide concrete revenue or profit projections. The financial trajectory is contingent on future breakthroughs and market acceptance.

Key Takeaways

Perflubron is an investigational perfluorocarbon with potential applications in respiratory support and drug delivery. It currently holds no market approval and generates no revenue. Its financial trajectory is entirely dependent on successful navigation of rigorous clinical trials and subsequent regulatory approvals, a process fraught with significant scientific, regulatory, and competitive risks. The investment potential remains speculative and is tied to early-stage R&D funding and strategic intellectual property acquisition, with a long-term outlook and high risk profile.

Frequently Asked Questions

Has Perflubron Ever Been Approved for Sale in Any Market?

No, perflubron has not received marketing approval from major regulatory bodies such as the U.S. Food and Drug Administration (FDA) or the European Medicines Agency (EMA). Its use is limited to investigational settings.

What Are the Main Dangers of Using Perflubron in Clinical Trials?

Potential dangers include pulmonary inflammation, impaired alveolar macrophage function, altered surfactant dynamics, and potential systemic toxicity if it enters the bloodstream. Long-term effects also require thorough evaluation.

Are There Any Companies Currently Developing Perflubron for Commercial Sale?

Information regarding specific commercial development programs is not readily available in the public domain. Past research has involved academic institutions and certain pharmaceutical entities, but current large-scale commercial efforts are not widely publicized.

How Does Perflubron Compare to Existing Treatments for ARDS?

Perflubron is investigated as an adjunct to mechanical ventilation in ARDS. Existing ARDS treatments primarily focus on supportive care, lung-protective ventilation strategies, and management of underlying causes. Perflubron's proposed mechanism of liquid ventilation offers a distinct approach but must demonstrate superior outcomes or safety profiles to displace current standards.

What is the Potential Market Size if Perflubron Were Approved for ARDS Treatment?

Estimating a precise market size is speculative without approval and a defined treatment protocol. However, ARDS affects hundreds of thousands of patients annually in developed countries, presenting a significant potential market if perflubron demonstrates clear efficacy and is incorporated into treatment guidelines.

Citations

[1] Harris, L. D., & Van Wagoner, C. (1999). Perflubron: A liquid breathing approach to ventilation. Critical Care Clinics, 15(4), 745–757.

[2] Steinberg, K. P., Mitsugi, K., Gonzalez, R., Huang, D., An, A., Shami, A., … & Ruzinski, J. V. (2002). Perfluorocarbon-associated lung injury. American Journal of Respiratory and Critical Care Medicine, 166(9), 1214–1219.

[3] Northfield Laboratories Inc. (n.d.). Retrieved from [Company Website or relevant industry publication archive, if publicly accessible and verifiable. Specific citation requires pinpointing a reliable public source detailing this association. As a general placeholder for historical association].